Bayer Heralds Potential Of BlueRock Parkinson's Stem Cell Therapy
Early-Stage Signs Show Promise
Bayer pharma research head Christian Rommel has told Scrip he was excited about the Phase I data on Parkinson's disease prospect bemdaneprocel, which is comprised of dopamine-producing neurons derived from pluripotent stem cells, but also advocated caution at this early stage.
